<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;A07E&quot;,&quot;href&quot;:&quot;atc/A07E.md&quot;},{&quot;label&quot;:&quot;budesonide&quot;}]"></div>

# budesonide

- **generic name:** budesonide
- **ATC codes:** `A07EA06`, `D07AC09`, `R01AD05`, `R03AK07`, `R03AK12`, `R03AK15`, `R03AL11`, `R03BA02`
- **DrugBank:** [DB01222](https://go.drugbank.com/drugs/DB01222) · **PubChem:** [CID 5281004](https://pubchem.ncbi.nlm.nih.gov/compound/5281004)
- **molar mass:** 430.5339 g/mol (C25H34O6) — DrugBank
- **groups:** approved, investigational

## About

Budesonide is a corticosteroid used for inflammatory conditions such as asthma, Crohn's disease, ulcerative colitis, and microscopic colitis. It is widely used and authorised in the European Union, where products cover areas such as IgA glomerulonephritis and esophageal diseases.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q422212](https://www.wikidata.org/wiki/Q422212) and the WHO ATC classification and the EMA medicines list; not checked by a person.</small>

## Molecules and molar masses

> The molar mass each model uses to convert mass to molar concentration and to form a metabolite molecule for molecule. Looked up, never estimated: DrugBank for the drug, the paper's own value or the PubChem entry matched to the paper's name for a metabolite.

| molecule | role | molar mass (g/mol) | formula | source | PubChem | records |
|---|---|---|---|---|---|---|
| budesonide | parent | 430.534 | C25H34O6 | DrugBank | [5281004](https://pubchem.ncbi.nlm.nih.gov/compound/5281004) | Rubin_2015 |

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-04 19:31 | 9:51 | 0/1/2 | 3/0/1 | 0/0/1 | 219,219/20,624 | ollama / qwen3.8:27b-mtp-q8_0 | 13 | 1/10 | 13/0 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--orange">needs review</span> <span class="pk-badge pk-badge--stale">stale</span><br><sub>STALE — current validate: needs_review</sub><br><sub>blocking: C5 dimensioned parameter(s) without a unit: Q22 — no SI value to build from</sub><br><sub>route_to: `human_review`</sub> | [Lönnebo_2007_reference](drugs/drug_budesonide/Budesonide_Lnnebo2007_reference.md) | — | 1-compartment (no model) | 3 | Lönnebo A et al., An integrated model for the effect of b…, British journal of clinical… (2007) | [10.1111/j.1365-2125.2007.02867.x](https://doi.org/10.1111/j.1365-2125.2007.02867.x) |
| <span class="pk-badge pk-badge--orange">needs review</span> <span class="pk-badge pk-badge--stale">stale</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.143). The first reading is what the record holds.">cross-check: disputed</span><br><sub>STALE — current validate: needs_review</sub><br><sub>blocking: C5 dimensioned parameter(s) without a unit: Q88 — no SI value to build from</sub><br><sub>route_to: `human_review`</sub> | [Rubin_2015_reference](drugs/drug_budesonide/Budesonide_Rubin2015_reference.md) | — | 1-compartment (no model) | 5 | Rubin DT et al., Budesonide Foam Has a Favorable Safety…, Digestive diseases and scie… (2015) | [10.1007/s10620-015-3868-5](https://doi.org/10.1007/s10620-015-3868-5) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--stale">stale</span><br><sub>STALE — current validate: rejected</sub><br><sub>blocking: C8 unreachable/orphan compartment or unlinked metabolite</sub><br><sub>route_to: `human_review`</sub> | [Back_2020_reference](drugs/drug_budesonide/Budesonide_Back2020_reference.md) | — | 2-compartment (no model) | 4 | Back HM et al., Exposure-Response and Clinical Outcome…, Pharmaceutics (2020) | [10.3390/pharmaceutics12040336](https://doi.org/10.3390/pharmaceutics12040336) |

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--species" title="In-vitro data (cells, tissue or microsomes), not measured in people (from the LLM relevance screen, p(non-human) 1.00).">in vitro</span> | [Donnelly_2010_CXCL8](drugs/drug_budesonide/pd_Donnelly_2010_CXCL8.md) | CXC chemokine ligand (CXCL)8 ← budesonide · direct Emax (saturable) effect | — | Donnelly LE et al., Effects of formoterol and salmeterol on…, The European respiratory jo… (2010) | [10.1183/09031936.00158008](https://doi.org/10.1183/09031936.00158008) |
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--species" title="In-vitro data (cells, tissue or microsomes), not measured in people (from the LLM relevance screen, p(non-human) 1.00).">in vitro</span> | [Donnelly_2010_GM_CSF](drugs/drug_budesonide/pd_Donnelly_2010_GM_CSF.md) | granulocyte macrophage-colony stimulating factor (GM-CSF) ← budesonide · direct Emax (saturable) effect | — | Donnelly LE et al., Effects of formoterol and salmeterol on…, The European respiratory jo… (2010) | [10.1183/09031936.00158008](https://doi.org/10.1183/09031936.00158008) |
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--species" title="In-vitro data (cells, tissue or microsomes), not measured in people (from the LLM relevance screen, p(non-human) 1.00).">in vitro</span> | [Donnelly_2010_TNF_alpha](drugs/drug_budesonide/pd_Donnelly_2010_TNF_alpha.md) | Tumour necrosis factor (TNF)-alpha ← budesonide · direct Emax (saturable) effect | — | Donnelly LE et al., Effects of formoterol and salmeterol on…, The European respiratory jo… (2010) | [10.1183/09031936.00158008](https://doi.org/10.1183/09031936.00158008) |
| <span class="pk-badge pk-badge--green">accepted (caveats)</span> | [Lönnebo_2007_ACTH](drugs/drug_budesonide/pd_L_nnebo_2007_ACTH.md) | ACTH ← budesonide · indirect response — drug inhibits the production of ACTH | — | Lönnebo A et al., An integrated model for the effect of b…, British journal of clinical… (2007) | [10.1111/j.1365-2125.2007.02867.x](https://doi.org/10.1111/j.1365-2125.2007.02867.x) |
| <span class="pk-badge pk-badge--green">extracted</span> | [Meibohm_1999_lymphocytes](drugs/drug_budesonide/pd_Meibohm_1999_lymphocytes.md) | blood lymphocytes ← budesonide · direct Emax (saturable) effect | — | Meibohm B et al., Mechanism-based PK/PD model for the lym…, International journal of cl… (1999) | — |
| <span class="pk-badge pk-badge--orange">needs review</span> | [Back_2020_ECP](drugs/drug_budesonide/pd_Back_2020_ECP.md) | sputum ECP ← budesonide · indirect response — drug inhibits the production of sputum ECP | — | Back HM et al., Exposure-Response and Clinical Outcome…, Pharmaceutics (2020) | [10.3390/pharmaceutics12040336](https://doi.org/10.3390/pharmaceutics12040336) |

## Pharmacogenomics (PGx)

| status | gene | affects | mechanism | detail | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--green" title="re-read by gpt-oss:120b (confirmed, agreement 1.0). The first reading is what the record holds.">cross-checked ✓</span> | **SUMF1** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [Ntenti_2025](drugs/drug_budesonide/pgx_Ntenti_2025_SUMF1_Q100.md) | Ntenti C et al., SUMF1 Common Variant rs793391 Is Associ…, International journal of mo… (2025) | [10.3390/ijms262010225](https://doi.org/10.3390/ijms262010225) |

<details class="pk-legend"><summary>What the PGx badges mean — evidence, and whether a model runs</summary><table><tbody><tr><td><span class="pk-badge pk-badge--green">quantitative</span></td><td>the paper gives the effect of each phenotype (or genotype) on a named model parameter — a θ per category.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">qualitative</span></td><td>the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">guideline estimate</span></td><td>the effect comes from a CPIC / DPWG dosing guideline, not from this paper's numbers.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">safety allele</span></td><td>a risk allele for an adverse reaction (an HLA type, G6PD deficiency …): it changes no PK/PD parameter.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>the extraction is incomplete or inconsistent.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted.</td></tr><tr><td><span class="pk-badge pk-badge--green">▶ simulatable</span></td><td>the paper's popPK model runs per phenotype in the browser (Simulation tab); its PGx Modelica model is under Models.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">model only</span></td><td>a PGx Modelica model exists but has no in-browser simulator.</td></tr></tbody></table></details>

<details class="legend">
<summary>What the PGx columns mean</summary>
<table><thead><tr><th>column</th><th>what it holds</th></tr></thead><tbody><tr><td><code>gene</code></td><td>the gene whose variants the record is about. One record per gene, so a paper reporting several genes appears on several rows.</td></tr><tr><td><code>affects</code></td><td>the PK or PD parameter the genotype SHIFTS, as an ontology Q-code plus its name — Q22 = clearance, Q27 = CL/F (apparent clearance), Q32 = Cmax, Q88 = AUC, Q40 = Fab, Q321 = EC50, Q322 = IC50, Q305 = kfm. The record's per-phenotype theta is a multiplier ON that parameter: a poor-metaboliser theta shifts this value, it does not supply one. Two values are NOT parameters — Q100 (NIL) is an association or risk finding with no parameter target, and `safety` is an adverse-reaction risk such as an HLA allele. A PA… id instead of a Q-code marks a record derived from a ClinPGx/PharmGKB guideline lookup rather than read out of the paper.</td></tr><tr><td><code>mechanism</code></td><td>how the gene acts: metabolism, transport, target, formation, safety_allele, or unknown.</td></tr><tr><td><code>detail</code></td><td>the paper stem, linking to the full record page.</td></tr><tr><th colspan="2" style="text-align:left;padding-top:10px">placeholders</th></tr><tr><td><code>not captured</code></td><td>the field is absent from the KB artifact — nothing was recorded. This is NOT the same as zero or empty: the value is unknown, not measured to be nothing.</td></tr><tr><td><code>—</code></td><td>deliberately not shown: the column does not apply to this row.</td></tr><tr><td><code>not verified</code></td><td>the record is not in an accepted state (see the badge and the note above the table); the numbers are shown as extracted, not endorsed.</td></tr></tbody></table>
</details>

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=budesonide) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | blood-brain barrier | `ABCB1` substrate, `SLCO1A2` substrate | DrugBank actor |
| absorption | kidney | `ABCB1` substrate | DrugBank actor |
| absorption | liver | `ABCB1` substrate | DrugBank actor |
| absorption | lung | <sub>named in DrugBank's ADME text</sub> | prose |
| absorption | placenta | `ABCB1` substrate | DrugBank actor |
| absorption | small intestine | `ABCB1` substrate, `SLCO1A2` substrate | DrugBank actor |
| absorption | testis | `ABCB1` substrate | DrugBank actor |
| distribution | blood | `ALB` binder | DrugBank actor |
| metabolism | kidney | `CYP3A5` inducer | DrugBank actor |
| metabolism | liver | `CYP2A6` inducer, `CYP2B6` inducer, `CYP2C19` inducer, `CYP2C8` inducer, `CYP2C9` inducer, `CYP3A4` inducer/substrate, `CYP3A5` inducer | DrugBank actor |
| metabolism | lung | `CYP1B1` inducer | DrugBank actor |
| metabolism | skin | `CYP1B1` inducer | DrugBank actor |
| metabolism | small intestine | `CYP3A4` inducer/substrate, `CYP3A5` inducer | DrugBank actor |
| excretion | kidney | `SLC22A8` substrate | DrugBank actor |
| excretion | liver | `ABCB11` substrate | DrugBank actor |

<sub>Actors without a tissue in the table: ANXA1 (substrate), NR3C1 (target), SERPINA6 (binder), SUMF1 (target).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 137 matched, 61 returned
- **screened:** 3  ·  **relevant:** 3
- **records:** 3  ·  extracted 0  ·  needs_review 2  ·  rejected 1  ·  stale 3
- **scholar-agent fallback query used:** not captured

## Full text wanted

_15 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Soulele_2018.pdf` | Soulele K et al., On the pharmacokinetics of two inhaled…, Pulmonary pharmacology & th… (2018) | popPK | 10 | [10.1016/j.pupt.2017.12.002](https://doi.org/10.1016/j.pupt.2017.12.002) | [29223508](https://pubmed.ncbi.nlm.nih.gov/29223508) | The paper describes a population PK study for budesonide, but the provided evidence contains only the abstract and no numeric parameter values. |
| `Meibohm_1999.pdf` | Meibohm B et al., Mechanism-based PK/PD model for the lym…, International journal of cl… (1999) | popPK | 8 | not captured | [10475139](https://pubmed.ncbi.nlm.nih.gov/10475139) | The study is a PK/PD investigation of budesonide in humans, but the evidence only reports PD parameters (EC50) and qualitative PK descriptions, lacking specific numeric PK values like clearance or volume. |
| `Daley-Yates_2004.pdf` | Daley-Yates PT et al., Relationship between systemic corticost…, Clinical therapeutics (2004) | pd | 5 | [10.1016/j.clinthera.2004.11.017](https://doi.org/10.1016/j.clinthera.2004.11.017) | [15639702](https://www.ncbi.nlm.nih.gov/pubmed/15639702) | metadata signals extractable PD data (pharmacodynamicmodel) |
| `Krishnaswami_2000.pdf` | Krishnaswami S et al., An interactive algorithm for the assess…, AAPS pharmSci (2000) | pd | 5 | [10.1208/ps020322](https://doi.org/10.1208/ps020322) | [11741238](https://www.ncbi.nlm.nih.gov/pubmed/11741238) | metadata signals extractable PD data (PK/PD) |
| `Stark_2006.pdf` | Stark JG et al., Pharmacokinetic/pharmacodynamic modelin…, Journal of pharmacokinetics… (2006) | pd | 5 | [10.1007/s10928-006-9013-5](https://doi.org/10.1007/s10928-006-9013-5) | [16633890](https://www.ncbi.nlm.nih.gov/pubmed/16633890) | metadata signals extractable PD data (pharmacodynamicmodel) |
| `Dilger_2006.pdf` | Dilger K et al., Multidrug resistance 1 genotype and dis…, Liver international : offic… (2006) | pgx | 8 | [10.1111/j.1478-3231.2005.01222.x](https://doi.org/10.1111/j.1478-3231.2005.01222.x) | [16584389](https://www.ncbi.nlm.nih.gov/pubmed/16584389) | metadata signals extractable PGX data (CYP3A, PK/PD-context) |
| `Chen_2018.pdf` | Chen N et al., In vitro drug-drug interactions of bude…, Xenobiotica; the fate of fo… (2018) | pgx | 7 | [10.1080/00498254.2017.1344911](https://doi.org/10.1080/00498254.2017.1344911) | [28730856](https://www.ncbi.nlm.nih.gov/pubmed/28730856) | metadata signals extractable PGX data (CYP1A2, PK/PD-context) |
| `Effinger_2021.pdf` | Effinger A et al., Predicting budesonide performance in he…, European journal of pharmac… (2021) | pgx | 7 | [10.1016/j.ejps.2020.105617](https://doi.org/10.1016/j.ejps.2020.105617) | [33164838](https://www.ncbi.nlm.nih.gov/pubmed/33164838) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Grigg_2024.pdf` | Grigg A, Cushing syndrome and tertiary adrenal i…, Internal medicine journal (2024) | pgx | 7 | [10.1111/imj.16344](https://doi.org/10.1111/imj.16344) | [38404123](https://www.ncbi.nlm.nih.gov/pubmed/38404123) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Moore_2013.pdf` | Moore CD et al., Metabolic pathways of inhaled glucocort…, Drug metabolism and disposi… (2013) | pgx | 7 | [10.1124/dmd.112.046318](https://doi.org/10.1124/dmd.112.046318) | [23143891](https://www.ncbi.nlm.nih.gov/pubmed/23143891) | metadata signals extractable PGX data (CYP3A, PK/PD-context) |
| `Seidegård_2012.pdf` | Seidegård J et al., Differentiating mucosal and hepatic met…, European journal of pharmac… (2012) | pgx | 7 | [10.1016/j.ejps.2012.04.005](https://doi.org/10.1016/j.ejps.2012.04.005) | [22538054](https://www.ncbi.nlm.nih.gov/pubmed/22538054) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Seymour_2021.pdf` | Seymour N et al., Prescribing intranasal steroids in HIV-…, The Journal of laryngology… (2021) | pgx | 7 | [10.1017/S0022215121001791](https://doi.org/10.1017/S0022215121001791) | [34387182](https://www.ncbi.nlm.nih.gov/pubmed/34387182) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Wilson_2017.pdf` | Wilson A et al., CYP3A4 Activity is Markedly Lower in Pa…, Inflammatory bowel diseases (2017) | pgx | 7 | [10.1097/MIB.0000000000001062](https://doi.org/10.1097/MIB.0000000000001062) | [28301431](https://www.ncbi.nlm.nih.gov/pubmed/28301431) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `König_2011.pdf` | König J et al., Role of organic anion-transporting poly…, Drug metabolism and disposi… (2011) | pgx | 5 | [10.1124/dmd.110.034991](https://doi.org/10.1124/dmd.110.034991) | [21430235](https://www.ncbi.nlm.nih.gov/pubmed/21430235) | metadata signals extractable PGX data (SLCO1B1) |
| `Resál_2023.pdf` | Resál T et al., Possible genetical predictors of effica…, Expert opinion on drug safe… (2023) | pgx | 5 | [10.1080/14740338.2023.2181336](https://doi.org/10.1080/14740338.2023.2181336) | [36811412](https://www.ncbi.nlm.nih.gov/pubmed/36811412) | metadata signals extractable PGX data (CYP3A4) |

<sub>queue written 2026-10-04T19:22:53.812566+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| PGx | Ardizzone_2002 | not_relevant | 0 | 0 | The paper is a general review of tolerability for ulcerative colitis drugs and does not report specific pharmacogenomic effects on the PK or PD of budesonide. |
| PGx | Back_2020 | not_relevant | 0 | 0 | The study tested ADRB2 genotype as a covariate but explicitly states that no significant covariate effect was found on the PK/PD model parameters. |
| PGx | Benido_2023 | not_relevant | 0 | 0 | The paper reports a drug-drug interaction (cobicistat inhibiting CYP3A4) causing iatrogenic Cushing's syndrome, not a pharmacogenomic effect of a gene variant on budesonide PK/PD. |
| popPK | Brunetti_2024 | irrelevant | 0 | 0 | The paper is a mathematical modeling study of leukemia stem cells where budesonide is a candidate drug for efficacy simulation, not a study reporting quantitative pharmacokinetic disposition parameters for budesonide. |
| PGx | Chen_2018 | not_relevant | 0 | 0 | The study investigates in vitro drug-drug interactions (transporters and CYPs) and does not report any pharmacogenomic effects (gene variants) on budesonide PK or PD. |
| PGx | Crowe_2012 | not_relevant | 0 | 0 | The study examines P-glycoprotein transport and induction in Caco-2 cells but does not report any pharmacogenomic effects (gene variants) on PK or PD parameters. |
| PGx | Czaja_2001 | not_relevant | 0 | 0 | The text mentions budesonide only in the context of clinical efficacy in autoimmune hepatitis, without reporting any pharmacogenomic effects on its PK or PD parameters. |
| PGx | Czaja_2005 | not_relevant | 0 | 0 | The paper is a review of treatment challenges in autoimmune hepatitis and does not report specific pharmacogenomic effects on budesonide PK/PD parameters. |
| popPK | Daley-Yates_2004 | irrelevant | 0 | 0 | no_text gate: only 144 chars of text extracted (&lt; 400) |
| PGx | Daval_2020 | not_relevant | 0 | 0 | The paper is a clinical trial protocol for budesonide efficacy in hyposmia and does not report pharmacogenomic effects on PK/PD parameters. |
| PGx | Dilger_2006 | not_relevant | 2 | 5 | The study concludes that common MDR1 polymorphisms do not affect budesonide disposition, reporting a null result rather than a pharmacogenomic effect. |
| popPK | Donnelly_2010 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of cytokine release and does not report pharmacokinetic parameters for budesonide. |
| PGx | Effinger_2021 | not_relevant | 0 | 0 | The paper investigates the impact of Crohn's disease pathophysiology (e.g., CYP3A4 abundance, albumin levels) on budesonide PK, not the effect of specific gene variants or genotypes. |
| PGx | Eskazan_2025 | not_relevant | 0 | 0 | The paper investigates the genetic risk of azathioprine-induced pancreatitis, not the pharmacokinetics or pharmacodynamics of budesonide. |
| PGx | Feng_2022 | not_relevant | 0 | 0 | The paper investigates diagnostic markers (FeNO, ECT) for asthma and does not report any pharmacogenomic effects on the pharmacokinetics or pharmacodynamics of budesonide. |
| PGx | Foti_2010 | not_relevant | 0 | 0 | The paper discusses budesonide only as a probe substrate for CYP3A4 drug-drug interaction studies and does not report any pharmacogenomic effects (gene variants) on its PK or PD parameters. |
| PGx | García-Martín_2013 | not_relevant | 2 | 1 | The paper is a general review of drug metabolism in allergic diseases and mentions budesonide only in the context of potential pre-systemic metabolism, without reporting specific pharmacogenomic effects on its PK/PD parameters. |
| PGx | Grigg_2024 | not_relevant | 0 | 0 | The paper describes a drug-drug interaction (posaconazole inhibiting CYP3A4) rather than a pharmacogenomic effect based on a specific gene variant or genotype. |
| popPK | Huang_2020 | irrelevant | 2 | 0 | The study reports non-compartmental PK parameters (AUC, Cmax) for a combination inhaler, lacking the specific compartmental or population PK parameters (CL, V, Q, ka) required for extraction. |
| PGx | Jönsson_1995 | not_relevant | 0 | 0 | The paper identifies the CYP3A enzyme responsible for budesonide metabolism but does not report any pharmacogenomic effects of specific gene variants or genotypes on PK/PD parameters. |
| popPK | Kelly_1998 | irrelevant | 2 | 0 | The paper is a review discussing general pharmacokinetic principles and relative potencies of inhaled corticosteroids without reporting specific quantitative PK parameter values (CL, V, etc.) for budesonide. |
| PD | Kelly_1998 | not_relevant | 2 | 0 | The text is a qualitative review discussing relative potencies and the flat nature of dose-response curves for inhaled corticosteroids, but it does not provide specific numeric PD parameters (e.g., EC50, Emax) or extractable concentration-effect data for budesonide. |
| PGx | Kong_2022 | not_relevant | 0 | 0 | The paper is a study protocol for a clinical trial evaluating the efficacy of a Traditional Chinese Medicine formula as an add-on to budesonide/formoterol, and does not report pharmacogenomic effects on PK/PD parameters. |
| popPK | Krishnaswami_2000 | irrelevant | 0 | 0 | no_text gate: only 116 chars of text extracted (&lt; 400) |
| PD | Krishnaswami_2000 | not_relevant | 0 | 0 | The paper describes an algorithm for assessing cumulative cortisol suppression but does not report a specific exposure-response or dose-response model with numeric PD parameters for budesonide. |
| PGx | König_2011 | not_relevant | 0 | 0 | The paper investigates the pharmacogenomics of mesalazine (5-ASA), not budesonide; budesonide is only mentioned as an inhibitor of mesalazine uptake. |
| popPK | Mehta_2018 | irrelevant | 0 | 0 | The study reports population PK parameters for fluticasone furoate, umeclidinium, and vilanterol, while budesonide is only mentioned as a comparator drug in the clinical trial design. |
| popPK | Meibohm_1999 | relevant | 8 | 2 | The study is a PK/PD investigation of budesonide in humans, but the evidence only reports PD parameters (EC50) and qualitative PK descriptions, lacking specific numeric PK values like clearance or volume. |
| popPK | Milara_2011 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of glucocorticoid resistance and cytokine release, reporting no pharmacokinetic parameters for budesonide. |
| PGx | Moore_2013 | not_relevant | 2 | 5 | The paper studies metabolism by CYP3A enzymes (CYP3A4/5/7) but does not report effects of specific genetic variants or genotypes on PK/PD parameters. |
| popPK | Ngai_2025 | irrelevant | 0 | 0 | The paper is a clinical efficacy comparison of kidney function outcomes (eGFR) and does not report any pharmacokinetic parameters for budesonide. |
| PGx | Onstenk_2015 | not_relevant | 0 | 0 | The paper investigates the association between AR-V7 status and cabazitaxel efficacy, not the effect of a gene variant on the PK or PD of budesonide. |
| popPK | Pu_2026 | irrelevant | 0 | 0 | The paper is a meta-analysis of adverse events and does not report pharmacokinetic parameters for budesonide. |
| PD | Pu_2026 | not_relevant | 4 | 2 | The paper reports a dose-response relationship for budesonide (cataract risk) using an Emax model in a meta-analysis, but the abstract does not provide the specific numeric PD parameters (Emax, ED50) required for extraction. |
| PGx | Resál_2023 | not_relevant | 4 | 2 | The paper reports an association between CYP3A5 genotype and clinical efficacy (CAI), but does not report specific pharmacokinetic (PK) or pharmacodynamic (PD) parameter changes (e.g., AUC, Cmax, receptor binding) or fitted effect sizes. |
| PGx | Seidegård_2012 | not_relevant | 0 | 0 | The study investigates the effect of a pharmacological inhibitor (ketoconazole) on budesonide metabolism, not the effect of a genetic variant or genotype. |
| PGx | Seymour_2021 | not_relevant | 0 | 0 | The paper discusses drug-drug interactions between intranasal steroids and HIV protease inhibitors, not pharmacogenomic effects of gene variants on PK/PD parameters. |
| popPK | Simeoli_2024 | relevant | 10 | 4 | The paper reports a population PK model for budesonide with specific parameter definitions (CL, V2, V3, Q, Ka), but the specific numeric estimates for these parameters are located in Supplementary Table S1 which is not included in the evidence, though secondary parameters (Cmax, AUC) are provided. |
| PGx | Somers_2007 | not_relevant | 0 | 0 | The paper compares enzyme expression and activity in lung vs. liver cells and does not report any pharmacogenomic effects (gene variants) on budesonide PK/PD parameters. |
| popPK | Soulele_2018 | relevant | 10 | 0 | The paper describes a population PK study for budesonide, but the provided evidence contains only the abstract and no numeric parameter values. |
| popPK | Stark_2006 | irrelevant | 0 | 0 | no_text gate: only 105 chars of text extracted (&lt; 400) |
| PGx | Vyhlidal_2021 | not_relevant | 0 | 0 | The paper investigates the impact of Crohn's disease inflammation on CYP3A4 expression and villous length, not the effect of a specific gene variant/genotype on budesonide PK/PD. |
| PGx | Wilson_2017 | not_relevant | 0 | 0 | The study investigates disease-dependent changes in CYP3A4 activity in Crohn's disease patients, not the effect of a specific gene variant or genotype on budesonide pharmacokinetics. |
| PGx | Wu_2009 | not_relevant | 0 | 0 | The paper assesses the repeatability (ICC) of asthma outcomes in a clinical trial but does not report any pharmacogenomic effects or gene-drug interactions. |
| PGx | Zimmermann_2009 | not_relevant | 0 | 0 | The paper investigates the induction of CYP3A4 by budesonide (drug-drug interaction potential) rather than the effect of a genetic variant on budesonide's PK/PD. |
| popPK | Zuo_2026 | irrelevant | 0 | 0 | The study is a comparative effectiveness analysis of clinical outcomes (proteinuria and eGFR) in IgA nephropathy, not a pharmacokinetic study, and reports no PK parameters for budesonide. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-10-04 19:23 UTC</sub>
